Literature DB >> 28066605

Relationship between survival and age in patients with idiopathic pulmonary fibrosis.

So-My Koo1, Soo-Taek Uh1, Dong Soon Kim2, Young Whan Kim3, Man Pyo Chung4, Choon Sik Park5, Sung Hwan Jeong6, Yong Bum Park7, Hong Lyeol Lee8, Jong Wook Shin9, Eun Joo Lee10, Jin Hwa Lee11, Yangin Jegal12, Hyun Kyung Lee13, Yong Hyun Kim14, Jin Woo Song2, Moo Suk Park15, Young Hwangbo16.   

Abstract

BACKGROUND: There is a debate that older patients with idiopathic pulmonary fibrosis (IPF) have a worse prognosis. We evaluated whether age affects the survival of patients with IPF.
METHODS: The Korean Interstitial Lung Disease (ILD) Research Group conducted a national survey to evaluate the clinical, physiological, radiological, and survival characteristics of patients with IPF. A total of 1,663 patients with IPF were stratified into three groups according to age: (I) <60 years (n=309); (II) 60-69 years (n=613); and (III) ≥70 years (n=741).
RESULTS: The 1-, 3- and 5-year observed survival rates were 83.0%, 62.6%, and 49.2% in the total population, respectively. The 1-, 3-, and 5-year relative survival rates were 85.7%, 69.1%, and 58.0% in all patients, respectively. The observed survival rate of the group ≥70 years of age was significantly lower than those of the other groups (P<0.001). In contrast, no significant difference in relative survival rate was detected among the three age groups. Compared with patients less than 60 years of age, patients with above 70 years of age had not increased risk of worse relative survival [P=0.252; hazard ratio (HR), 1.11; 95% confidence interval (CI), 0.76-1.64].
CONCLUSIONS: The prognosis of patients above 70 years of age with IPF was not different to that of patients less than 60 years of age, using relative survival rate. Age may not affect survival in patients with IPF.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis (IPF); age factors; prognosis; relative survival; survival analysis

Year:  2016        PMID: 28066605      PMCID: PMC5179452          DOI: 10.21037/jtd.2016.11.40

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.

Authors:  Roland M du Bois; Derek Weycker; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Alex Kartashov; Lisa Lancaster; Paul W Noble; Ganesh Raghu; Steven A Sahn; Javier Szwarcberg; Michiel Thomeer; Dominique Valeyre; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2011-08-15       Impact factor: 21.405

3.  Association between occupational dust exposure and prognosis of idiopathic pulmonary fibrosis: a Korean national survey.

Authors:  Sang Hoon Lee; Dong Soon Kim; Young Whan Kim; Man Pyo Chung; Soo Taek Uh; Choon Sik Park; Sung Hwan Jeong; Yong Bum Park; Hong Lyeol Lee; Jeong Sup Song; Jong Wook Shin; Nam Soo Yoo; Eun Joo Lee; Jin Hwa Lee; Yangin Jegal; Hyun Kyung Lee; Moo Suk Park
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

4.  Clinical findings and outcomes in patients with possible usual interstitial pneumonia.

Authors:  Jin Wook Lee; Esmeralda Shehu; Juarda Gjonbrataj; Young Eun Bahn; Byung Hak Rho; Mi-Young Lee; Won-Il Choi
Journal:  Respir Med       Date:  2015-02-14       Impact factor: 3.415

Review 5.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

6.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model.

Authors:  T E King; J A Tooze; M I Schwarz; K R Brown; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

7.  Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts.

Authors:  D W Mapel; W C Hunt; R Utton; K B Baumgartner; J M Samet; D B Coultas
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

8.  Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003.

Authors:  Amy L Olson; Jeffrey J Swigris; Dennis C Lezotte; Jill M Norris; Carla G Wilson; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2007-05-03       Impact factor: 21.405

Review 9.  Abnormal lung aging in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.

Authors:  Rosa Faner; Mauricio Rojas; William Macnee; Alvar Agustí
Journal:  Am J Respir Crit Care Med       Date:  2012-05-10       Impact factor: 21.405

10.  Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007.

Authors:  Yu Jin Kim; Jeong-Woong Park; Sun Young Kyung; Sang Pyo Lee; Man Pyo Chung; Young Hwan Kim; Jae Ho Lee; Yong Chul Kim; Jong Seon Ryu; Hong Lyeol Lee; Choon Sik Park; Soo-Tak Uh; Young Chul Lee; Kwan Hyung Kim; Young Joon Chun; Young Bum Park; Dong Soon Kim; Yongjin Jegal; Jin Hwa Lee; Moo Suk Park; Sung Hwan Jeong
Journal:  J Korean Med Sci       Date:  2012-06-29       Impact factor: 2.153

View more
  2 in total

Review 1.  Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis.

Authors:  Qiang Zheng; Ingrid A Cox; Julie A Campbell; Qing Xia; Petr Otahal; Barbara de Graaff; Tamera J Corte; Alan K Y Teoh; E Haydn Walters; Andrew J Palmer
Journal:  ERJ Open Res       Date:  2022-03-14

2.  TGF-β1-induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression.

Authors:  Yapei Huang; Yan Xie; Peter W Abel; Peng Wei; Jocelyn Plowman; Myron L Toews; Heather Strah; Aleem Siddique; Kristina L Bailey; Yaping Tu
Journal:  Biochem Pharmacol       Date:  2020-07-24       Impact factor: 5.858

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.